Angiotensin II Type 1 Receptor Blockers, Diabetic Nephropathy, Glucose Metabolism, Obese, Type 2 Diabetes
Conditions
Keywords
obese female, Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers, Adiponectin
Brief summary
Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).
Detailed description
it would be a prospective cohort study. According to BMI, all the women, aged\>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.
Interventions
DRUGlosartan
losartan, 100mg daily,
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetic nephropathy * CKD at stage 1\ 4
Exclusion criteria
* Type 1 diabetes or nondiabetic renal disease * An elevated plasma K level.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GFR, HbA1c and the adiponectin concentration. | 6 month |
Outcome results
None listed